Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials by Gettinger, Scott N., MD, Huber, Rudolf M., MD, Kim, Dong-Wan, XX, Bazhenova, Lyudmila, XX, Hansen, Karin Holmskov, XX, Tiseo, Marcello, XX, Langer, Corey J., XX, Paz-Ares Rodríguez, Luis G., XX, West, Howard L., XX, Reckamp, Karen L., XX, Weiss, Glen J., XX, Smit, Egbert F., XX, Hochmair, Maximilian J., XX, Kim, Sang-We, XX, Ahn, Myung-Ju, XX, Kim, Edward S., XX, Groen, Harry J.M., XX, Pye, Joanna, XX, Liu, Yuyin, XX, Zhang, Pingkuan, XX, Vranceanu, Florin, XX, Camidge, D. Ross, XX

Get full text